| ALDEYRA THERAPEUT.DL-,001 |
| USA |
| Gesundheit |
| US01438T1060 / A111X8 |
| 137 (Frankfurt) / ALDX (NASDAQ) |
| FRA:137, ETR:137, 137:GR, NASDAQ:ALDX |
| - |
| https://www.aldeyra.com/ |
|
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases. Its current pipeline centers on small-molecule and related drug candidates for ophthalmology and other inflammatory co..
>Volltext.. |
| 34.23 Mio. EUR |
| -1.76 Mio. EUR |
| - |
| -17.89 Mio. EUR |
| -17.24 Mio. EUR |
| -0.29 EUR |
| 0.41 Mio. EUR |
| 36.94 Mio. EUR |
| -17.24 Mio. EUR |
| 5.2 |
| - |
| 54.13% |
| - |
| - |
| - |
| ALDEYRA |
| 14.11.26 |
|